Zacks Investment Research downgraded shares of TherapeuticsMD (NASDAQ:TXMD) from a hold rating to a sell rating in a research note published on Friday, January 12th.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Other research analysts have also recently issued reports about the company. BidaskClub raised TherapeuticsMD from a strong sell rating to a sell rating in a report on Tuesday, December 12th. Noble Financial reissued a buy rating on shares of TherapeuticsMD in a report on Thursday, November 30th. Deutsche Bank set a $9.00 price objective on TherapeuticsMD and gave the company a buy rating in a report on Wednesday, December 20th. Oppenheimer set a $10.00 price target on TherapeuticsMD and gave the company a buy rating in a report on Wednesday, December 20th. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $31.00 price target on shares of TherapeuticsMD in a report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $14.50.
Shares of TherapeuticsMD (NASDAQ TXMD) traded down $0.15 during midday trading on Friday, hitting $5.36. The company’s stock had a trading volume of 2,384,256 shares, compared to its average volume of 1,838,752. The company has a market capitalization of $1,192.36, a PE ratio of -13.39 and a beta of 1.23. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average cost of $6.21 per share, with a total value of $31,050.00. Following the completion of the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 23.92% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. increased its position in TherapeuticsMD by 3.9% in the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares during the period. Amalgamated Bank increased its position in TherapeuticsMD by 7.2% in the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares during the period. Legal & General Group Plc increased its position in TherapeuticsMD by 6.5% in the second quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock worth $298,000 after purchasing an additional 3,441 shares during the period. The Manufacturers Life Insurance Company increased its position in TherapeuticsMD by 3.4% in the second quarter. The Manufacturers Life Insurance Company now owns 123,580 shares of the company’s stock worth $651,000 after purchasing an additional 4,058 shares during the period. Finally, Rhumbline Advisers increased its position in TherapeuticsMD by 3.5% in the second quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock worth $967,000 after purchasing an additional 6,232 shares during the period. Hedge funds and other institutional investors own 73.86% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “TherapeuticsMD (TXMD) Downgraded to “Sell” at Zacks Investment Research” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/05/zacks-investment-research-downgrades-therapeuticsmd-txmd-to-sell.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.